查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1908129

泛基因組檢測和多基因panel檢測（MGPT）市場規模、佔有率和趨勢分析報告：按檢測方法、適應症、最終用途、地區和細分市場預測，2025-2033年

Pan-genomic And Multi-gene Panel Testing Market Size, Share & Trends Analysis Report By Test, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

泛基因組檢測與多基因panel檢測（MGPT）市場概述

2024 年全球泛基因組檢測/MGPT 市場規模估計為 89.6 億美元，預計到 2033 年將達到 231.9 億美元。

預計2025年至2033年間，該市場將以11.37%的複合年成長率成長，主要促進因素包括腫瘤學和精準醫學領域臨床應用的不斷擴大、對全面基因資訊的需求日益成長、分子譜分析在治療方案製定中的應用日益廣泛，以及高通量定序技術的進步。與傳統的單基因檢測相比，針對數十至數百個癌症相關基因的多基因檢測能夠提供更深入、更全面的分子資訊。

臨床檢驗的檢測方法，例如 FoundationOne CDx（約 324 個基因）和 MSK-IMPACT（468 個基因），目前已在 CLIA 認證的檢查室中常規用於識別具有治療意義的基因組改變。這有助於提高治療方法方案的個人化程度，使臨床醫生能夠透過一次全面的分析來識別罕見但可靶向的突變，而無需耗費大量時間進行一系列單獨的檢測。因此，領先的癌症中心正在將 MGPT/泛基因組檢測納入其腫瘤診療流程。真實世界的結果證實了這種做法的顯著影響。根據美國臨床腫瘤學會 (ASCO) 2024 年 11 月的一項研究，在接受病理學家主導的全面基因組分析 (CGP) 的患者中，有 36% 的患者僅根據其基因組譜中的生物標記觀察就接受了標靶治療(TT) 或免疫腫瘤治療 (IO)。

此外，推動泛基因組檢測/多基因檢測（MGPT）市場成長的關鍵因素之一是定序成本的快速持續下降。根據美國國家人類基因組研究所（NHGRI）的報告，次世代定序（NGS）技術的顯著進步已將單一人類基因定序成本從2001年的約1億美元降至2024年的約6億美元。雖然全面的多基因檢測曾經是一項專業且昂貴的流程，但成本的大幅降低使其成為患者和診斷檢查室都能輕鬆獲得且負擔得起的工具。因此，遺傳性癌症檢測正從主要在專業遺傳中心使用轉變為預防醫學和腫瘤學工作流程中的標準組成部分。

全球遺傳性疾病和新興遺傳性疾病盛行率的不斷上升是泛基因組學和多基因全基因組檢測（MGPT）市場最強勁的驅動力之一。據估計，全球約有4億人患有罕見遺傳性疾病，3-5%的新生兒受到先天性或遺傳性疾病的影響。隨著越來越多的疾病的遺傳基礎逐漸明晰，醫療保健系統正迅速將廣泛的多基因和全基因組檢測納入早期診斷、攜帶者篩檢、治療決策和長期疾病管理的標準通訊協定。人們對林奇症候群、李-弗勞梅尼症候群以及BRCA相關乳癌和卵巢癌等遺傳性癌症症候群的認知不斷提高，顯著促進了這些檢測方法在腫瘤學領域的應用。由於5-10%的癌症被歸類為遺傳性癌症，而BRCA1/2基因突變可使乳癌風險增加高達70%，卵巢癌風險增加高達40%，因此，積極全面的基因組篩檢的需求從未如此迫切。

此外，基因組數據的日益複雜化，特別是來自泛基因組檢測和多基因檢測（MGPT）的數據，帶來了巨大的挑戰，因為解讀數百萬個突變需要臨床基因組學和生物資訊學的高級專業知識。許多實驗室難以留住足夠的分子遺傳學家、臨床遺傳學家和生物資訊學家來應對如此繁重的工作量。根據發表在PMC上的《腫瘤學次世代定序（NGS）全球應用框架》，訓練有素的臨床分子遺傳學家和基因組分析師的短缺阻礙了NGS的廣泛應用。此外，定序和生物資訊學流程的基礎設施差異加劇了這個問題，使得各實驗室難以維持一致的品質。

目錄

第1章 泛基因組檢測與MGPT市場：調查方法與範圍

2.泛基因組檢測與MGPT市場：執行摘要

  • 市場概覽
  • 檢查
  • 適應症概述
  • 最終用途概述
  • 競爭格局概述

3.泛基因組檢測/多基因檢測市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 腫瘤學和精準醫學的臨床應用
    • 定序成本下降和技術進步
    • 遺傳性疾病的發生率正在上升。
  • 市場限制因素分析
    • 數據解讀的複雜性和基因組學專家的短缺
    • 監管挑戰、合規負擔和缺乏標準化
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章 泛基因組檢測與MGPT市場：依檢測方式分類的估算與趨勢分析

  • 泛基因組檢測與MGPT市場：依檢測方法進行的變異分析
  • 泛基因組/全EXOME組檢測板
  • 綜合遺傳疾病檢測
  • 腫瘤多基因檢測
  • 藥物基因體學（PGx）檢測組

第5章 泛基因組檢測與MGPT市場：依適應症分類的估算與趨勢分析

  • 泛基因組檢測與MGPT市場：依適應症分類的變異分析
  • 腫瘤學
  • 心臟病學/心肌病
  • 神經病學和神經遺傳學
  • 罕見且未確診的遺傳疾病
  • 生殖攜帶者篩檢
  • 新生兒和兒童基因組學

6. 泛基因組檢測和MGPT市場：按最終用途分類的估算和趨勢分析

  • 泛基因組檢測與MGPT市場：依最終用途分類的差異分析
  • 醫院的基因檢查室
  • 獨立診斷檢查室
  • 專業基因組學中心
  • 其他

7. 泛基因組檢測與MGPT市場：按地區分類的業務分析

  • 區域市場概覽
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合資
    • 資金籌措
  • 主要企業市佔率分析（2024 年）
  • 公司熱力圖分析
  • 公司簡介
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fulgent Genetics
    • Ambry Genetics（Tempus）
    • GeneDx
    • Baylor Genetics
    • Natera
    • Caris Life Sciences
    • Foundation Medicine, Inc.（Roche）
    • Guardant Health
Product Code: GVR-4-68040-830-3

Pan-genomic And Multi-gene Panel Testing Market Summary

The global pan-genomic & multi-gene panel testing market size was estimated at USD 8.96 billion in 2024 and is projected to reach USD 23.19 billion by 2033, growing at a CAGR of 11.37% from 2025 to 2033, driven by driven by clinical adoption in oncology and precision medicine and increasing demand for comprehensive genetic insights, rising use of molecular profiling in treatment planning, and advancements in high-throughput sequencing technologies. Compared to traditional single-gene assays, multi-gene panels that often span dozens to hundreds of cancer-related genes provide deeper and more comprehensive molecular insights.

Clinically validated assays, such as FoundationOne CDx (approximately 324 genes) and MSK-IMPACT (468 genes), are now routinely used in CLIA-certified laboratories to identify actionable genomic alterations. This has improved therapeutic matching, enabling clinicians to identify rare but targetable variants through a single, comprehensive analysis, rather than relying on sequential, time-consuming individual tests. As a result, major cancer centers are incorporating multi-gene and pan-genomic testing into their oncology workflows. Real-world results demonstrate the quantifiable impact of this adoption. A November 2024 study from the American Society of Clinical Oncology (ASCO) found that 36% of patients who underwent pathologist-directed comprehensive genomic profiling (CGP) received a targeted therapy (TT) or immuno-oncology (IO) agent simply because of biomarker findings in their genomic profile.

Moreover, the one of the key factors propelling the growth of the pan-genomic and multi-gene panel testing market is the swift and ongoing decrease in sequencing costs. The National Human Genome Research Institute (NHGRI) reports that significant advancements in next-generation sequencing (NGS) technologies have enabled the cost of sequencing a human genome to decrease from nearly USD 100 million in 2001 to approximately USD 600 in 2024. Comprehensive multi-gene testing was once a specialized and expensive process, but thanks to this significant decrease, it is now a readily available and reasonably priced tool for both patients and diagnostic laboratories. As a result, hereditary cancer testing has shifted from being used primarily in specialized genetics centers to becoming a standard component of preventive care and oncology workflows.

The rising global prevalence of genetic disorders, both inherited and newly occurring, has become one of the strongest drivers of the pan-genomic and multi-gene panel testing market. An estimated 400 million people worldwide suffer from rare genetic disorders, and 3-5% of all newborns are impacted by congenital or inherited genetic conditions. Healthcare systems are quickly incorporating extensive multi-gene and pan-genomic testing into standard protocols for early diagnosis, carrier screening, therapeutic decision-making, and long-term disease management as the genetic basis of more diseases becomes more apparent. Adoption in oncology is being greatly increased by the growing recognition of hereditary cancer syndromes, such as Lynch syndrome, Li-Fraumeni syndrome, and BRCA-associated breast/ovarian cancer. With 5-10% of all cancers classified as hereditary, and BRCA1/2 mutations increasing breast cancer risk by up to 70% and ovarian cancer risk by up to 40%, the need for proactive and comprehensive genomic screening has never been more compelling.

In addition, the increasing complexity of genomic data, particularly from whole-genome and large multi-gene panel tests, poses a significant challenge because interpreting millions of variants necessitates extensive clinical genomics and bioinformatics expertise. Many laboratories struggle to find enough molecular geneticists, clinical geneticists, and bioinformaticians to handle the workload. According to a global adoption framework for NGS in oncology published in PMC, a shortage of well-trained personnel, such as clinical molecular geneticists and genomic analysts, impedes widespread implementation. Moreover, infrastructural gaps in sequencing and bioinformatics pipelines exacerbate the issue, making it difficult to maintain consistent quality across laboratories.

Global Pan-genomic And Multi-gene Panel Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pan-genomic & multi-gene panel testing market report based on test, application, end-use, and region:

  • Test Outlook (Revenue, USD Million, 2021 - 2033)
  • Pan-Genomic / Whole Exome Based Panels
  • Comprehensive Hereditary Disease Panels
  • Oncology Multi-Gene Panels
  • Pharmacogenomics (PGx) Panels
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiology & Cardiomyopathy
  • Neurology and Neurogenetics
  • Rare & Undiagnosed Genetic Diseases
  • Reproductive Carrier Screening
  • Newborn & Pediatric Genomics
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital-based Genetic Labs
  • Independent Diagnostic Labs
  • Specialty Genomic Centers
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Pan-Genomic & Multi-Gene Panel Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test
      • 1.1.1.2. Application Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Pan-Genomic & Multi-Gene Panel Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test
  • 2.3. Application Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Pan-Genomic & Multi-Gene Panel Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Clinical adoption in oncology and precision medicine
    • 3.4.2. Falling sequencing costs & tech advances
    • 3.4.3. Increasing burden of genetic disorders & rising
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complexity of data interpretation & shortage of skilled genomic specialists
    • 3.5.2. Regulatory challenges, compliance Burdens & lack of standardization
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Pan-Genomic & Multi-Gene Panel Testing Market: Test Estimates & Trend Analysis

  • 4.1. Pan-Genomic & Multi-Gene Panel Testing Market: Test Movement Analysis
  • 4.2. Pan-Genomic / Whole Exome Based Panels
    • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Comprehensive Hereditary Disease Panels
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Oncology Multi-Gene Panels
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmacogenomics (PGx) Panels
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pan-Genomic & Multi-Gene Panel Testing Market: Application Estimates & Trend Analysis

  • 5.1. Pan-Genomic & Multi-Gene Panel Testing Market: Application Movement Analysis
  • 5.2. Oncology
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Cardiology & Cardiomyopathy
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Neurology and Neurogenetics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Rare & Undiagnosed Genetic Diseases
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Reproductive Carrier Screening
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Newborn & Pediatric Genomics
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Pan-Genomic & Multi-Gene Panel Testing Market: End Use Movement Analysis
  • 6.2. Hospital-based Genetic Labs
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Independent Diagnostic Labs
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Specialty Genomic Centers
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pan-Genomic & Multi-Gene Panel Testing Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Pan-Genomic & Multi-Gene Panel Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Illumina, Inc.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Thermo Fisher Scientific, Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fulgent Genetics
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Ambry Genetics (Tempus)
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. GeneDx
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Baylor Genetics
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Natera
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Caris Life Sciences
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Foundation Medicine, Inc. (Roche)
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Guardant Health
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 5 Global Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 9 North America Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 12 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 15 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 16 Canada Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 18 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 22 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 25 UK Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 UK Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 28 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 Germany Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 31 France Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 34 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 37 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 40 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Sweden Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 43 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Norway Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 46 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Denmark Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 50 Asia-Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 53 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 56 China Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 59 India Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 62 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 Australia Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 65 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Thailand Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 68 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 South Korea Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 72 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 75 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 78 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 82 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 MEA Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 85 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 South Africa Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 91 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By Test, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Pan-Genomic & Multi-Gene Panel Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pan-genomic & multi-gene panel testing market segmentation
  • Fig. 2 Data analysis test technique
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD biomarker modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Pan-genomic & multi-gene panel testing market Test outlook key takeaways
  • Fig. 20 Pan-genomic & multi-gene panel testing market: Test movement analysis
  • Fig. 21 Pan-genomic / whole exome based panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Comprehensive hereditary disease panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Oncology multi-gene panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Pharmacogenomics (PGx) panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Pan-genomic & multi-gene panel testing market: Application outlook key takeaways
  • Fig. 26 Pan-genomic & multi-gene panel testing market: Application movement analysis
  • Fig. 27 Oncology market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Cardiology & cardiomyopathy market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Neurology and neurogenetics market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Rare & undiagnosed genetic diseases market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Reproductive carrier screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Newborn & pediatric genomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Pan-genomic & multi-gene panel testing market: End Use outlook key takeaways
  • Fig. 34 Pan-genomic & multi-gene panel testing market: End Use movement analysis
  • Fig. 35 Hospital-based genetic labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Independent diagnostic labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Specialty genomic centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Middle East
  • Fig. 41 Middle East market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Saudi Arabia key country dynamics
  • Fig. 43 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 UAE key country dynamics
  • Fig. 45 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Kuwait key country dynamics
  • Fig. 47 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Oman key country dynamics
  • Fig. 49 Oman market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Qatar key country dynamics
  • Fig. 51 Qatar market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Rest of Middle East key country dynamics
  • Fig. 53 Rest of Middle East market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Market differentiators
  • Fig. 55 Key company market share analysis